Endpoints News 15. Dez. 2025 FDA speeds up review of J&J's multiple myeloma combo treatment following positive data
Endpoints News 15. Dez. 2025 With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels
Endpoints News 15. Dez. 2025 Aviceda's geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?
Endpoints News 15. Dez. 2025 Areteia Therapeutics to wind down after terminating Phase 3 asthma studies
Endpoints News 15. Dez. 2025 Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA
Endpoints News 15. Dez. 2025 Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront
Endpoints News 15. Dez. 2025 Western genetic medicine makers turn to Chinese investigator-initiated trials
Endpoints News 13. Dez. 2025 Eli Lilly’s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and more
Endpoints News 12. Dez. 2025 340B sales grew 23% last year, and court battle over pilot program intensifies
Endpoints News 12. Dez. 2025 Covid vaccine deaths review sent to top of FDA, but with far less certain conclusions, sources say
Endpoints News 12. Dez. 2025 CHMP calls to reject Anavex's Alzheimer’s pill over impurities, side effects and weak efficacy